All data are based on the daily closing price as of February 20, 2026
s

Samsung Biologics

207940.KO
690.82 USD
-0.19
-0.03%

Overview

Last close
690.82 usd
Market cap
31.98B usd
52 week high
761.21 usd
52 week low
634.23 usd
Target price
690.82 usd

Valuation

P/E
N/A
Forward P/E
75.7576
Price/Sales
17.6346
Price/Book Value
6.4993
Enterprise Value
54.17B usd
EV/Revenue
14.2455
EV/EBITDA
28.2734

Key financials

Revenue TTM
3.80B usd
Gross Profit TTM
2.13B usd
EBITDA TTM
1.86B usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
13.09B usd
Net debt
205.82M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
  • Symbol
    207940.KO
  • Exchange
    KO
  • Isin
    KR7207940008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. John Chongbo Rim
  • Headquarter
    Incheon
  • Web site
    https://samsungbiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top